How Long Does Semaglutide Take to Work?

If you are asking how long it takes for semaglutide to work, the honest answer is that it works in stages, not all at once. In the STEP 1 trial of once-weekly semaglutide 2.4 mg, measurable weight loss appeared from the very first post-randomization assessment at week 4 and continued building for more than a year, used together with a reduced-calorie diet and increased physical activity. Some people notice appetite changes within the first few weeks, but the larger, headline-level results in that trial accrued over many months as the dose was gradually increased. This article is educational information, not medical advice, and individual results vary.

What does the trial timeline actually show?

STEP 1 (published in NEJM in 2021) randomized 1,961 adults with overweight or obesity and without type 2 diabetes to once-weekly subcutaneous semaglutide 2.4 mg or placebo, both alongside lifestyle intervention, for 68 weeks. Per the primary STEP 1 paper, weight began separating from placebo early and kept dropping steadily.

That primary paper reported that weight loss was visible from week 4 onward and reached its lowest point (nadir) at approximately week 60 in the semaglutide group before leveling off through week 68. So the practical takeaway is twofold: early movement can show up within the first weeks, but the bulk of the change in STEP 1 took the better part of a year.

Phase	What STEP 1 observed (semaglutide 2.4 mg)
Week 4 (first measurement)	Weight loss already detectable vs. placebo
First several weeks	Drug levels building toward steady state; some people report appetite changes
Months 2-12	Loss accumulates as the dose is titrated upward
~Week 60	Average weight reached its lowest point (nadir)
Week 68 (trial end)	About 14.9-15% mean reduction, with diet and activity

That ~15% figure belongs to STEP 1 specifically and is a trial average paired with lifestyle changes, not a promise. It is a different drug and trial from tirzepatide; if you are comparing the two molecules, our tirzepatide vs semaglutide overview keeps the figures attributed to their correct trials.

Why does semaglutide build up gradually?

Two things explain the slow, steady curve. First, the pharmacology: per the FDA-approved Wegovy label, semaglutide has a terminal half-life of roughly one week. That is why it is injected only once weekly, and it means blood levels rise gradually over the first month or so before reaching a steady state. You are not at full exposure on day one.

Second, the dose itself is intentionally escalated. The FDA Wegovy label starts low and steps up about every four weeks so the body can adjust:

Weeks	Wegovy dose (once weekly)
1-4	0.25 mg (starting dose)
5-8	0.5 mg
9-12	1 mg
13-16	1.7 mg
17+	2.4 mg (maintenance)

Because the maintenance dose studied in STEP 1 is typically not reached until around month four, it makes sense that the most pronounced effects show up later rather than in week one. For a fuller breakdown of the titration, see our semaglutide dosing chart. Note that Ozempic, the type 2 diabetes form of semaglutide, follows a different escalation and a maximum of 2 mg per its own FDA label, so those numbers should not be mixed with Wegovy’s weight-management dosing.

What might I notice in the first few weeks?

Some people report reduced appetite or earlier fullness within the first weeks, which is consistent with weight loss being detectable by week 4 in STEP 1 and with drug levels building over the first month. This is qualitative and individual, not a guaranteed onset, and it can coincide with side effects as the body adjusts. If you want a sense of how the adjustment period tends to unfold, our companion piece on how long semaglutide side effects last covers that timeline separately.

Whether and when you notice anything depends on your starting dose, how titration goes, your diet and activity, and your individual physiology. None of that should be self-managed; dose changes are determined by your prescriber.

How much weight did people lose, and how varied was it?

In STEP 1, per the primary paper, mean change in body weight from baseline to week 68 was -14.9% with semaglutide 2.4 mg versus -2.4% with placebo, an absolute change of about -15.3 kg versus -2.6 kg, used with a reduced-calorie diet and increased physical activity. But averages hide a lot of spread.

A subsequent responder analysis reported the observed distribution of weight loss within the semaglutide group at week 68. The categories broke down roughly like this:

Weight-loss category at week 68	Share of semaglutide group
20% or more	34.8%
15% to under 20%	19.9%
10% to under 15%	20.0%
5% to under 10%	17.5%

Those observed categories together mean roughly nine in ten participants in that analysis lost at least 5% of body weight. That range, from under 5% to 20% or more, is exactly why “individual results vary” is not a throwaway phrase. Your trajectory may look different from the average.

Why does weight loss plateau?

A plateau is expected, not a failure. In STEP 1 the average weight-loss curve reached its nadir around week 60 and then leveled off, which is a normal pattern of metabolic adaptation as the body settles at a lower weight. Plateaus arrive at different points for different people, and the timing seen in a trial average will not map onto every individual.

This is also why semaglutide is studied and labeled for use with a reduced-calorie diet and increased physical activity. The FDA indication frames the medication as one part of a broader plan, not a standalone fix. If you are weighing non-GLP-1 options as part of that bigger picture, our overview of peptides for weight loss offers context.

Does it keep working if I stop?

This is where the timeline question becomes a duration question. In the STEP 1 trial extension, participants who stopped semaglutide regained a mean of 11.6 percentage points of body weight within one year of withdrawal; the net change from baseline at week 120 was -5.6% for the semaglutide group versus -0.1% for placebo. The study authors concluded that ongoing treatment is required to maintain improvements in weight and health.

In other words, how long semaglutide “works” is partly a function of how long it is used, and that decision, like the dose and the overall plan, is provider-determined rather than something to self-manage.

A note on FDA-approved versus compounded semaglutide

Wegovy and Ozempic (semaglutide) are FDA-approved. Compounded semaglutide is not FDA-approved, and the FDA has not evaluated it for safety, quality, or efficacy. The FDA determined the semaglutide shortage resolved on February 21, 2025 (and removed tirzepatide from the shortage list in October 2024), and large-scale compounding under the shortage provisions is no longer permitted. The trial figures cited here come from studies of the FDA-approved 2.4 mg injection and should not be assumed to apply to compounded products.

Frequently asked questions

How soon does semaglutide start working?

In STEP 1, weight loss was measurable from the first post-randomization assessment at week 4, and some people report appetite changes within the first weeks as drug levels build toward steady state over roughly the first month. This is qualitative, not a guaranteed onset, and individual results vary.

How long until I see significant weight loss?

In STEP 1, the average loss accumulated over many months and reached its lowest point around week 60, with about 14.9-15% mean reduction at 68 weeks, used with a reduced-calorie diet and increased physical activity. That is a trial average; your timeline may differ and is determined with your provider.

Why does the dose start so low?

Per the FDA Wegovy label, the dose is escalated from 0.25 mg up to the 2.4 mg maintenance dose in roughly four-week steps to help the body adjust. The maintenance dose studied in STEP 1 is usually reached around month four, which is part of why effects tend to build gradually.

What happens if I stop taking semaglutide?

In the STEP 1 extension, participants who stopped regained a mean of 11.6 percentage points of body weight within a year, and the authors concluded ongoing treatment is required to maintain improvements. Whether to continue, pause, or change treatment is a decision for a licensed provider.

Is it normal for weight loss to plateau?

Yes. In STEP 1 the average curve leveled off after reaching its nadir around week 60, reflecting expected metabolic adaptation. Plateaus occur at different points for different people, and the trial-average timing will not match everyone.

Is compounded semaglutide the same as Wegovy?

No. Wegovy is FDA-approved; compounded semaglutide is not FDA-approved, and the FDA has not evaluated it for safety, quality, or efficacy. The figures in this article come from trials of the FDA-approved injection and should not be assumed to apply to compounded versions.